RTX-224 Monotherapy in Patients With Solid Tumors

• Status: Recruiting
• Trial end date: 2024-07-30

Summary

This is an open-label, multidose, first-in-human (FIH), Phase 1/2 study of RTX-224 for the treatment of patients with relapsed or refractory (R/R), or locally advanced solid tumors.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Rubius Therapeutics